Wilson (Zack) Ray, M.D., Associate Professor of Neurosurgery and a member of The INSPIRE Study Steering Committee, performed the implantation approximately ten hours after the injury occurred. Paul Santiago, M.D., is the Principal Investigator at this site. Mark Perrin, InVivo’s Chief Executive Officer and Chairman, said, “Once again, it has been demonstrated that Neuro-Spinal Scaffold implantation is readily performed within twelve hours post-injury, which is earlier than most standard of care spine stabilization surgery.
We look forward to diligently monitoring this patient’s outcomes and enrolling additional patients into this landmark study.” Any forward-looking statements contained herein are based on current expectations, and are subject to a number of risks and uncertainties. Factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the volatility of the trading price of the company’s common stock; the company’s ability to successfully open additional clinical sites for enrollment and to enroll additional patients; the timing of the Institutional Review Board process; the company’s ability to obtain FDA approval to modify its pivotal trial protocol or to conduct a future study; the company’s ability to commercialize its products; the company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the company’s products and technology in connection with the treatment of spinal cord injuries; the availability of substantial additional funding for the company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and other risks associated with the company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies identified and described in more detail in the company’s Annual Report on Form 10-K for the year ended December 31, 2014, and its other filings with the SEC, including the company’s Form 10-Qs and current reports on Form 8-K. The company does not undertake to update these forward-looking statements. InVivo Therapeutics Holdings Potbelly. is a seek and clinical-stage biomaterials and biotechnology telephoner with a core manipulation of spinal cord injuries. For more details, chit-chat www.invivotherapeutics.com.
About the Neuro-Spinal Scaffold™
For more information, please visit the company’s ClinicalTrials.gov registration site: http://clinicaltrials.gov/ct2/show/study/NCT02138110
InVivo Therapeutics Holdings Corp. (NVIV) today announced that a sixth patient has been enrolled into The INSPIRE Study (InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury) at the Barnes-Jewish Hospital at Washington University Medical Center in St. Louis, Missouri. The family was founded in two g quint with proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Fetch of Technology, and Joseph P. Vacanti, M.D., who so was at Boston Children’s Hospital and who now is machine-accessible with Massachusetts Worldwide Hospital. In 2011, the companion earned the David S. Apple Observe from the American Spinal Trauma Association for its contact contribution to spinal cord damage medication. In 2015, the company’s investigational Neuro-Spinal Scaffold stock the two m xv Becker’s Healthcare Backbone Twisting Confront. The publicly-traded company is headquartered in Cambridge, MA.
“We were open to get the patient into the operation in such an expeditious way thanks to the experienced wound and neurosurgical teams at the Barnes-Jewish Hospital,” Dr. Ray aforementioned. “The implantation summons was lame and the patient is recovering well. I savour forrader to following the patient’s feeler.” Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as “believe,” “anticipate,” “intend,”
Misstate dates and figures 1353 written as 1953.60 as 60 7. buyessay.org review Rrlig flyttfirma p andra sidan kommer ofta ange en tidsperiod som kommer som brukar kallas en leveransfnster, speciellt pianoflytt. The IB extending essay writing unique takes time and vigor.
“estimate,” “will,” “may,” “should,” “expect,” “designed to,” “potentially,” and similar expressions, and include statements regarding the safety and effectiveness of the Neuro-Spinal Scaffold and patient recovery following implantation.